Elypta appoints Volker Liebenberg as CMO


Elypta, a Swedish diagnostics company aiming to commercialize the first metabolism-based liquid biopsy for early detection of any cancer, announced the appointment of Dr. Volker Liebenberg as Chief Medical Officer.

“We are truly delighted to have Dr. Liebenberg join the team. He brings a wealth of experience in IVD development to Elypta and shares our belief in the potential for liquid biopsies to drive early detection of cancer,” says Karl Bergman, Elypta CEO.

“It feels great to join a high performing team, that is pursuing an amazing diagnostic opportunity. GAG biomarkers hold promise to detect multiple cancers early, and I look forward to bring in my experience to drive their adoption,” says Dr. Liebenberg.

Dr. Liebenberg joins Elypta from Illumina, where he acted as the head of the Medical Affairs team in Europe, the Middle East, and Africa (EMEA). At Elypta, Volker will oversee clinical development of Elypta’s platform for earlier detection of multiple cancers. Volker is a physician with more than 20 years of academic and industry experience in the research and commercialization of biomarkers. Volker has previously worked with several other molecular diagnostic companies including QIAGEN GmbH, Thermo Fisher Scientific Inc., and Epigenomics AG, with medical responsibility across multiple indications in oncology, infectious diseases, and prenatal screening.


Leave a Reply

Your email address will not be published.